BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pulmonary Hypertension Associated with Interstitial Lung Disea
 se readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Pulmonary Hypertensio
 n Associated with Interstitial Lung Disease\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07333183-544@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Mosliciguat: Phase 2 readout est. (NCT07333183)
DESCRIPTION:Mosliciguat\, phase 2\, Pulmonary Hypertension Associated with 
 Interstitial Lung Disease.\nStudy: A Study of Mosliciguat in Combination W
 ith Inhaled Treprostinil in PH-ILD\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/mosliciguat#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073331
 83
URL:https://assetmemo.bio/drug/mosliciguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07473700-542@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20271121
DTEND;VALUE=DATE:20271122
SUMMARY:Fc-relaxin fusion protein (TX45): Phase 2 readout est. (NCT07473700
 )
DESCRIPTION:Fc-relaxin fusion protein (TX45)\, phase 2\, Pulmonary Hyperten
 sion Associated with Interstitial Lung Disease.\nStudy: Study of TX000045 
 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disea
 se\nEstimated primary completion: 21 November 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/fc-relaxin-fusion-protein-tx45#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07473700
URL:https://assetmemo.bio/drug/fc-relaxin-fusion-protein-tx45#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475781-543@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Mirivadelgat: Phase 2 readout est. (NCT06475781)
DESCRIPTION:Mirivadelgat\, phase 2\, Pulmonary Hypertension Associated with
  Interstitial Lung Disease.\nStudy: Study to Evaluate Safety and Efficacy 
 of Mirivadelgat in PH-ILD (Windward)\nEstimated primary completion: Februa
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirivadelgat
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064
 75781
URL:https://assetmemo.bio/drug/mirivadelgat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05798923-550@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:LAM-001: Phase 2 readout est. (NCT05798923)
DESCRIPTION:LAM-001\, phase 2\, Pulmonary Hypertension Associated with Inte
 rstitial Lung Disease.\nStudy: LAM-001 for the Treatment of Pulmonary Hype
 rtension Associated With Interstitial Lung Disease (PH-ILD)\nEstimated pri
 mary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/lam-001#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05798923
URL:https://assetmemo.bio/drug/lam-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816185-544@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20290128
DTEND;VALUE=DATE:20290129
SUMMARY:Mosliciguat: Phase 3 readout est. (NCT07816185)
DESCRIPTION:Mosliciguat\, phase 3\, Pulmonary Hypertension Associated with 
 Interstitial Lung Disease.\nStudy: A Phase 3 Trial of Inhaled Mosliciguat 
 in PH-ILD (PHrontier)\nEstimated primary completion: 28 January 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/mosliciguat#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07816185
URL:https://assetmemo.bio/drug/mosliciguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285655-522@assetmemo.bio
DTSTAMP:20261121T010000Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Treprostinil (L606): Phase 3 readout est. (NCT07285655)
DESCRIPTION:Treprostinil (L606)\, phase 3\, Pulmonary Hypertension Associat
 ed with Interstitial Lung Disease.\nStudy: A Phase 3 Study to Evaluate the
  Safety and Efficacy L606 in Participants With PH-ILD\nEstimated primary c
 ompletion: July 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /treprostinil-l606#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07285655
URL:https://assetmemo.bio/drug/treprostinil-l606#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
